Effect of FK409, a Novel Nitric Oxide Donor, on Acute Experimental Myocardial Ischemia
スポンサーリンク
概要
- 論文の詳細を見る
The anti-ischemic heart effect of (±)-(<I>E</I>)-4-ethyl-2-[(<I>E</I>)-hydroxyimino]-5-nitro-3-hexenamide (FK409), a novel nitric oxide donor, was studied in dog and rat preparations in vivo and in vitro. In anesthetized dogs with partially occluded coronary artery that were subjected to atrial pacing at a constant blood pressure, FK409 (1-100 μg/kg, i.v.) suppressed the ST-segment elevation on epicardial electrocardiograms. Glyceryl trinitrate (GTN; 10, 32 μg/kg) or dipyridamole (1000 μg/kg) failed to suppress the ST-segment elevation, although continuous i.v. infusion of GTN (32, 100 μg/kg/min) was effective. FK409 also suppressed the ST-segment elevation induced by methacholine in anesthetized rats by both i.v. (10, 100 μg/kg) and intraduodenal (i.d., 100, 1000 μg/kg) injections, while GTN (100 μg/kg, i.v.; 1000 μg/kg, i.d.) was effective only by the i.v. route. FK409 (0.32 μg/kg/min, i.v.) and GTN (10 μg/kg/min) increased the blood flows of the endomyocardium (ENDO) and the epicardium (EPI) and the flow ratio of ENDO/EPI in the ischemic zone in anesthetized dogs with occluded coronary artery. Furthermore, in isolated dog vascular preparations, FK409 (4.6×10<SUP>-10</SUP>-4.6×10<SUP>-7</SUP>M) had a greater vasorelaxing effect on the large coronary artery [2.0-2.5-mm outer diameter (od)] than on the small coronary artery (0.3-0.5-mm od) or the saphenous artery. The results suggest that FK409 protects against acute experimental myocardial ischemia through relaxation of the large conductive coronary artery, and may be a useful oral drug for the treatment of angina pectoris.
著者
-
KOHSAKA MASANOBU
Pharmacological Research Laboratories and Exploratory Research Laboratories
-
YAMAMOTO Takao
Pharmacological Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.,
-
Ozaki Reiko
Pharmacological Division, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
Isono Toyokazu
Pharmacological Division, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
Sato Natsuki
Pharmacological Division, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
Koibuchi Yasushi
Pharmacological Division, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
Sakai Shigeru
Pharmacological Division, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
Mori Jo
Pharmacological Division, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
Ohtsuka Minoru
Pharmacological Division, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
Kohsaka Masanobu
Pharmacological Division, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
関連論文
- Comparative Characterization of New Glutaryl 7-ACA and Cephalosporin C Acylases
- Cloning and Nucleotide Sequencing of New Glutaryl 7-ACA and Cephalosporin C Acylase Genes from Pseudomonas Strains
- Isolation of Soil Strains Producing New Cephalosporin Acylases
- Direct Production of 7-Aminodeacetylcephalosporanic Acid by Acremonium chrysogenum Hm178(Microbiology & Fermentation Industry)
- A Novel 7-β-(4-Carboxybutanamido)-Cephalosporanic Acid Acylase Isolated from Pseudomonas Strain C427 and Its High-Level Production in Escherichia coli
- Microscopic IR-Reflection Study of Oxygen Doping Effect Induced by Laser Irradiation on YBa_2Cu_3O_y, Surface
- Agents for the Treatment of Overactive Detrusor. IX. Synthesis and Pharmacological Properties of Metabolites of N-tert-Butyl-4,4-diphenyl-2-cyclopentenylamine (FK584) in Human Urine
- Direct Observation of ^O Tracer Diffusion in a YBa_2Cu_3O_y Single Crystal by Secondary Ion Mass Spectrometry
- Cloning and Nucleotide Sequences of the Complementary and Genomic DNAs for the Alkaline Protease from Acvemonium chrysogenum(Microbiology & Fermentation Industry)
- Effect of FK409, a Novel Nitric Oxide Donor, on Acute Experimental Myocardial Ischemia